-
3 days ago | 
ascopost.com | Matthew Stenger
In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in patients with metastatic colorectal cancer. The TILs are edited to enable knockout of CISH, which encodes cytokine-inducible SH2-containing protein, a novel intracellular immune checkpoint target.
-
3 days ago | 
ascopost.com | Matthew Stenger
In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among patients with a range of solid tumors.
-
1 week ago | 
ascopost.com | Matthew Stenger
In a study reported in Journal of Clinical Oncology, Sperduto and colleagues analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Assessment (GPA).
-
1 week ago | 
ascopost.com | Matthew Stenger
In a Children’s Oncology Group (COG) study (AAML1831) reported in Journal of Clinical Oncology, Huang et al found that hematopoietic stem cell transplantation (HSCT) was associated with improved outcomes in pediatric patients with high-risk acute myeloid leukemia (AML).
-
1 week ago | 
ascopost.com | Matthew Stenger
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study DetailsThe study involved data from all unplanned acute care encounters (emergency department visits and hospitalizations) among patients with a primary cancer diagnosis at University of California, San Francisco between January 2013 and December 2023.
-
1 week ago | 
ascopost.com | Matthew Stenger
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates.
-
1 week ago | 
ascopost.com | Matthew Stenger
In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in definitive chemoradiation therapy for patients with locally advanced non–small cell lung cancer (NSCLC).
-
2 weeks ago | 
ascopost.com | Matthew Stenger
In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer Database data on patients with high-risk, stage I–III, estrogen receptor–low breast cancer who received (neo)adjuvant chemotherapy and did or did not initiate endocrine therapy.
-
3 weeks ago | 
ascopost.com | Matthew Stenger
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study DetailsIn this study, men between the ages of 55 and 69 from primary care centers were invited to participate between March and July 2019.
-
3 weeks ago | 
ascopost.com | Matthew Stenger
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma.The primary analysis of the trial showed that D-VMP significantly improved progression-free survival vs VMP in this setting.
